State Street Corp Acquires 52,528 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

State Street Corp increased its stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) by 12.4% during the third quarter, Holdings Channel.com reports. The institutional investor owned 476,439 shares of the company’s stock after buying an additional 52,528 shares during the period. State Street Corp’s holdings in Werewolf Therapeutics were worth $1,010,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. Millennium Management LLC raised its position in Werewolf Therapeutics by 96.4% in the second quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock worth $2,709,000 after acquiring an additional 544,881 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Werewolf Therapeutics by 103.1% in the 2nd quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock worth $417,000 after purchasing an additional 86,800 shares during the period. Walleye Capital LLC lifted its stake in Werewolf Therapeutics by 10.7% in the third quarter. Walleye Capital LLC now owns 108,968 shares of the company’s stock valued at $231,000 after purchasing an additional 10,528 shares during the last quarter. SG Americas Securities LLC bought a new position in Werewolf Therapeutics during the third quarter valued at $29,000. Finally, Rhumbline Advisers bought a new position in Werewolf Therapeutics during the second quarter valued at $79,000. Institutional investors own 64.84% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Werewolf Therapeutics in a research note on Tuesday, November 19th.

Werewolf Therapeutics Price Performance

HOWL opened at $1.56 on Friday. The firm has a 50-day moving average price of $1.96 and a 200-day moving average price of $2.18. Werewolf Therapeutics, Inc. has a twelve month low of $1.38 and a twelve month high of $8.19. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29. The company has a market capitalization of $69.52 million, a price-to-earnings ratio of -1.02 and a beta of 0.30.

Werewolf Therapeutics Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.